申请人:Novo Nordisk A/S
公开号:US05198451A1
公开(公告)日:1993-03-30
Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein Y is ##STR2## wherein R.sup.1 and R.sup.2 independently are C.sub.3-8 cycloalkyl phenyl or thienyl all of which may be optionally substituted with halogen, trifluoromethyl, C.sub.1-16 alkyl or C.sub.1-6 alkoxy; s is 1, 2 or 3; x is --CH.sub.2 --, --O-- or ##STR3## -wherein R.sup.3 is hydrogen or C.sub.1-6 -alkyl; r is 2, 3 or 4; R.sup.4 and R.sup.5 each represents hydrogen or may together represent a bond and R.sup.6 is OH or C.sub.1-8 -alkoxy; and pharmaceutically acceptable acid addition salts are potent inhibitors of GABA uptake from the synaptic cleft.
N-取代的杂环羧酸和其酯,其中取代的烷基链构成N-取代基的一部分,因此这些化合物具有一般式I ##STR1## 其中Y为##STR2## 其中R.sup.1和R.sup.2独立地为C.sub.3-8环烷基苯或噻吩基,所有这些基可能选择性地被卤素、三氟甲基、C.sub.1-16烷基或C.sub.1-6烷氧基取代;s为1、2或3;x为--CH.sub.2--、--O--或##STR3## -其中R.sup.3为氢或C.sub.1-6-烷基;r为2、3或4;R.sup.4和R.sup.5各代表氢或可共同代表键,R.sup.6为OH或C.sub.1-8-烷氧基;和药学上可接受的酸盐是GABA从突触间隙中摄取的有效抑制剂。